Algo version: 0.98b
CANbridge Pharmaceuticals is listed at the HKSE Exchange
CANbridge Pharmaceuticals [1228.HK]
HKSE Sector: Healthcare Industry:Biotechnology

Is CANbridge Pharmaceuticals stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for CANbridge Pharmaceuticals 10 years ago, but if you had invested on Thursday 9th of December 2021 when the price was HKD8.90, you would have made a loss of HKD-8.58 per share or -96.35%

No, the average daily trading liquidity for CANbridge Pharmaceuticals is HKD25 158 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

CANbridge Pharmaceuticals has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for CANbridge Pharmaceuticals to be high [0.85 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.